Skip to search formSkip to main contentSkip to account menu

Proprotein Convertase 9

Known as: Convertase 9, Proprotein, Proprotein Convertase, Subtilisin Kexin Type 9, Proprotein Convertase 9 [Chemical/Ingredient] 
A proprotein convertase that is essential for CHOLESTEROL homeostasis. It binds to and is required for the lysosomal degradation of the LDL RECEPTOR… 
National Institutes of Health

Related topics

Related topics

9 relations
In BloodPCSK9 geneProcess of secretionantagonists & inhibitors

Narrower (1)

PCSK9 protein, human

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Treatment of hyperlipidemia with proprotein convertase subtilisin/kexin type 9 inhibitor in a patient with nephrotic syndrome: a case report.
We report the case of a patient with nephrotic syndrome and toxic epidermal necrolysis (TEN) caused by statin use. The associated… 
Review
2019
Review
2019
Implications for REDUCE IT in clinical practice.
2019
2019
Significant regression of carotid artery stenosis after treatment with proprotein convertase subtilisin/kexin type 9 serine protease inhibitor
Cerebrovascular accident is the fifth most common cause of death and the leading cause of disability in the United States.1… 
Review
2019
Review
2019
Should we Consider Lipoprotein (a) in Cardiovascular Disease Risk Assessment in Patients with Familial Hypercholesterolaemia?
BACKGROUND Familial hypercholesterolaemia (FH) is a genetically determined lipid disorder, affecting 1 per 200-500 individuals in… 
2019
2019
2979The effect of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors on endothelial progenitor cells
Endothelial progenitor cells (EPCs) have an important role in the process of vascular repair by promoting re… 
2018
2018
SEX-RELATED DIFFERENCE IN THE REGRESSION OF CORONARY ATHEROSCLEROSIS WITH THE PCSK9 INHIBITOR, EVOLOCUMAB: INSIGHTS FROM GLAGOV
Review
2017
Review
2017
PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook
The clinical reality of residual risk despite statin (HMG-CoA reductase inhibitor) therapy and emergence of statin intolerance… 
2016
2016
Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia—Brief Report
Objective—Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors lower low-density lipoprotein (LDL) cholesterol in the… 
2016
2016
Dietary high oleic canola oil supplemented with docosahexaenoic acid attenuates plasma proprotein convertase subtilisin kexin type 9 (PCSK9) levels in participants with cardiovascular disease risk: A…
2014
2014
Nucleic acid delivery systems based on poly(galactosyl ureaethyl methacrylate-b-dimethylamino ethyl methacrylate) diblock copolymers.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)